AgeneBio Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

AgeneBio General Information

Description

Developer of innovative therapeutics designed to help patients at risk for neurological and psychiatric conditions. The company's therapeutics prevent neurodegeneration and preserve and restore cognitive function for underserved patients battling amnestic mild cognitive impairment, the symptomatic pre-dementia stage and other neurological and psychiatric diseases, enabling individuals afflicted with neurological and psychiatric diseases like Alzheimer's disease, dementia and other memory disorders to get treatments.

Contact Information

Website
www.agenebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 601 South Charles Street
  • Baltimore, MD 21230
  • United States
+1 (410)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 601 South Charles Street
  • Baltimore, MD 21230
  • United States
+1 (410)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AgeneBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Private 01-Feb-2026 Completed Clinical Trials - Phase 3
12. Grant 01-Sep-2020 Completed Clinical Trials - Phase 3
11. Grant 11-Sep-2019 Completed Clinical Trials - Phase 3
10. Grant 15-Aug-2019 Completed Clinical Trials - Phase 3
9. Grant 30-Sep-2018 Completed Clinical Trials - General
8. Grant 30-Sep-2018 Completed Clinical Trials - General
7. Grant 13-Sep-2017 Completed Clinical Trials - General
6. Later Stage VC 27-Jul-2016 Completed Clinical Trials - General
5. Grant 15-Sep-2015 $8.4M $7.8M Completed Clinical Trials - General
4. Later Stage VC (Series A) 17-Oct-2014 $7.5M $7.8M Completed Clinical Trials - General
To view AgeneBio’s complete valuation and funding history, request access »

AgeneBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative therapeutics designed to help patients at risk for neurological and psychiatric conditions. The
Drug Discovery
Baltimore, MD
4 As of 2025

Boston, MA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AgeneBio Competitors (30)

One of AgeneBio’s 30 competitors is CervoMed, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CervoMed Formerly VC-backed Boston, MA
CereSpir Venture Capital-Backed New York, NY
Confluence Pharmaceuticals Venture Capital-Backed Arcadia, IN
Cognition Therapeutics Formerly VC-backed New York, NY
TauRx Pharmaceuticals Private Equity-Backed Aberdeen, United Kingdom
You’re viewing 5 of 30 competitors. Get the full list »

AgeneBio Patents

  • 149

    Total Documents Applications and Grants

  • Total Patents Families

  • 80

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

AgeneBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024207082-A1 Methods for preventing or slowing the progression of cognitive decline or impairment in subjects Pending 13-Jan-2023
EP-4648767-A1 Methods for preventing or slowing the progression of cognitive decline or impairment in subjects Pending 13-Jan-2023
US-20240238246-A1 Methods for preventing or slowing the progression of cognitive decline or impairment in subjects Pending 13-Jan-2023
WO-2024151951-A1 Methods for preventing or slowing the progression of cognitive decline or impairment in subjects Inactive 13-Jan-2023
AU-2023324882-A1 Benzazepine derivatives, compositions, and methods for treating cognitive impairment Pending 19-Aug-2022 C07D487/14
To view AgeneBio’s complete patent history, request access »

AgeneBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AgeneBio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
National Institute on Aging Government
Sahsen Ventures Venture Capital Minority
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital
To view AgeneBio’s complete investors history, request access »

Ready to get started?

Request a free trial

AgeneBio FAQs

  • When was AgeneBio founded?

    AgeneBio was founded in 2008.

  • Where is AgeneBio headquartered?

    AgeneBio is headquartered in Baltimore, MD.

  • What is the size of AgeneBio?

    AgeneBio has 4 total employees.

  • What industry is AgeneBio in?

    AgeneBio’s primary industry is Drug Discovery.

  • Is AgeneBio a private or public company?

    AgeneBio is a Private company.

  • What is AgeneBio’s current revenue?

    The current revenue for AgeneBio is .

  • How much funding has AgeneBio raised over time?

    AgeneBio has raised $8.7M.

  • Who are AgeneBio’s investors?

    National Institutes of Health, National Institute on Aging, Sahsen Ventures, and Alzheimers Drug Discovery Foundation have invested in AgeneBio.

  • Who are AgeneBio’s competitors?

    CervoMed, CereSpir, Confluence Pharmaceuticals, Cognition Therapeutics, and TauRx Pharmaceuticals are some of the 30 competitors of AgeneBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process